Boron neutron capture therapy (BNCT) has recently received considerable attention due to a highly selective therapy for treating cancer in clinical trial.
1 BNCT is binary therapy based on the combination of two components: nonradioactive boron ( 10 B) atom and low energy thermal neutron. As the thermal neutron irradiates 10 B atom, alpha (α)-particle and lithium ion ( 7 Li) are generated as well as substantial sufficient energy to damage a cell is produced.
2
Since the α-particle and Li ion traverse within confined distance (i.e. ~5-10 μm) corresponding diameter of tumor cell, BNCT can be utilized to selectively kill tumor cells but minimize irradiation damage on normal cells.
Major challenge in BNCT is to find a safe and selective boron delivery agent. BNCT agents for successful therapy have been required to accumulate high 10 B concentration in tumor (i.e., 10-30 μg of 10 B per gram of tumor) with high selectivity (i.e., tumor to normal cell ratio is 5:1) and with low toxicity. 3 Currently successful BNCT agents are sodium borocaptate (BSH) and boronophenylalanine (BPA), which are ongoing for clinical trial (phase I/II), but they have also some limitations such as insufficient selectivity, low retention time in tumor, low chemical stability due to air-oxidation in BSH, and need of large amount of drug administration due to low boron percentage (5%) in BPA. 4 Although a number of new BNCT agents are developing to address these problems, demands of novel boron carrier in BNCT still remain.
Folate receptor (FR) has been an important therapeutic target for cancer treatment, because many cancer cells exhibit high levels of FR on their surface while FR expression in most normal cells is highly restricted.
5 Also, folic acid is able to bind to FR with extremely high affinity (K D ≈ 10 −10 M) and transport a drug in cell via an endocytic process. Folate-conjugated drugs could be selectively delivered to highly FR-expressing cancer cell. Therefore, folic acid natural compound might be potentially a non-toxic and selective boron delivery agent in BNCT.
On the other hands, dicarba-closo-dodecaborane (C 2 B 10 H 12 ; commonly referred to as carborane; exists ortho, meta, and para isomers) has been widely considered for developing new BNCT agents, because use of carborane has benefits such as high boron content, stability to catabolism, hydrophobic interaction enhancement, and extraordinary chemical and thermal stability. Specifically, the volume of carborane has not only topologically similar with that of a phenyl ring rotating about its C1-C4 axis, but also the diameter of carborane is 5.25 Å in comparison with that of phenyl ring is 4.72 Å.
7 Therefore, typical strategy has been to prepare carborane-conjugated biomolecules or to introduce carborane cluster in place of aryl group.
In the past, we have reported the synthesis and testing of new class of ortho-carborane-conjugated aminobenzoylglutamate as a BNCT agent. 8 The carborane analog of folate showed several advantages such as sufficient water solubility for in vitro test, low toxicity towards melanoma cells (IC 50 6.9 × 10 −4 M), and boron uptake of 0.37 μg B per 10 6 cells. Especially, the aminobenzoylglutamate moiety in the carborane seems to be very important natural carrier for water solubility, and cell-uptake mechanism in the biological system. Therefore, we hypothesized that the new class of folate compounds, introduced ortho-carborane in place of heteroaromatics, could be potentially promising BNCT agent to deliver on FR or internalize in cell nucleus as well as to minimize damage to normal cell for successful cancer therapy. On the other hands, a computational design quite recently showed that ortho-carborane could fit in the active site of human dihydrofolate reductase (hDHFR).
9
In this paper, as our continuous work, we present the Figure 1 . Structures of the designed ortho-carborane compounds (7, 13 and 16).
Notes
synthetic and biological data of new class of ortho-carborane analog of folate sodium salt as a potential BNCT agent. The ortho-carboranes as shown in Figure 1 were synthesized from 4-aminobenzoic acid and 4-hydroxybenzoic acid. All carborane compounds were tested as mono-or disodium salt forms to confer water solubility.
Results and Discussion
The first carborane compounds (7a and 7b) have been synthesized as shown in Scheme 1 (also as shown in supplementary materials). The formylation reaction of 4-aminobenzoic acid in the presence of acetic anhydride and formic acid at room temperature (rt) gave 4-(N-formylamino)-benzoic acid (2) in 92% yield. The in situ cesium salt of 2 easily transformed benzylated compound (3) in 88% yield. The N-alkylation reaction with propargyl bromide in acetone in the presence of tetra-n-butylammonium bromide under reflux for 12 h gave the propargyl product (4a) in 87% yield. Also, the same reaction of 3b with 4-pentynyl p-toluenesulfonate (tosylate) leaded to 4b in 63% yield. The orthocarboranes readily formed in 77% and 72% yields, respectively, by refluxing the solution of propargylation products and decaborane (B 10 H 14 ) in toluene and acetonitrile cosolvent. Benzyl protecting groups of 5a and 5b were easily deprotected via catalytic transfer hydrogenation in the presence of 10% Pd/C and 4.5% formic acid in ethanol and the 6a and 6b were obtained in quantitative yields. The two acids were quantitatively transformed into sodium salts (7a and 7b) to increase the water solubility for in vitro toxicity and boron uptake tests. 10, 11 In the end, the ortho-carborane analogs of folate sodium salts (7a and 7b) were prepared from 4-aminobenzoic acid through 7 steps in 54% and 36% overall yields, respectively.
The second target compounds of ortho-carborane sodium salts (13a-c) were prepared from the 4-hydroxybenzoic acid (8) as shown in Scheme 2. The cesium salt of 4-hydroxybenzoic acid was treated with benzyl bromide in DMF at rt and the benzyl (4-hydroxy)benzoate (9) formed in 93% yield. The O-alkylation with propargyl bromide (n = 1), 4-pentynyl tosylate (n = 2) or 5-butynyl tosylate (n = 3) gave the propargylated compounds (10a-c) in 96% (n = 1), 68% (n = 2), and 61% (n = 3) yields, respectively. The carboranization of the esters (10a-c) with decaborane in refluxing toluene and acetonitrile produced the ortho-carborane (11a-c) in 84% (n = 1), 68% (n = 2), and 72% (n = 3) yields, respectively. The carboranyl benzoic acids (12a-c) were quantitatively created via catalytic transfer hydrogenation in the presence of 10% Pd/C and 4.5% formic acid in ethanol. Also, the resulting three acids (12a-c) were quantitatively transformed into the sodium salts (13a-c) to confer the sufficient water solubility for the in vitro tests.
12-14 In fact, the ortho-carborane sodium salts (13a-c) were prepared from 4-hydroxybenzoic acid through 6 steps in 68%, 39%, Scheme 1. Synthesis of ortho-carborane sodium salts (7) from 4-aminobenzoic acid: (a) Ac2O in HCOOH at rt for 6 h, 92%; (b) Cs2CO3 in MeOH at rt for 30 min, quantitative; (c) BnBr in DMF at rt for 48 h, 88%; (d) (n-Bu)4NBr, propargyl bromide (n = 1) or 4-pentynyl ptoluenesulfonate (n = 3), K2CO3 in acetone at reflux for 12 h, 87% (n = 1), 63% (n = 3); (e) B10H14 in CH3CN and toluene at reflux for 7 h, 77% (n = 1), 72% (n = 3); (f) Pd/C and 4.5% HCOOH in MeOH at rt for 3 h, 99% (n = 1) and 99% (n = 3); (g) NaHCO3 in MeOH and H2O at rt for 0.5 h, 97% (n = 1) and 98% (n = 3).
Scheme 2. Synthesis of ortho-carborane sodium salts (13) from 4-hydroxybenzoic acid: (a) Cs2CO3 in MeOH at rt for 30 min, quantitative; (b) BnBr in DMF at rt for 18 h, 93%; (c) Propargyl bromide (n = 1) or 3-butynyl p-toluenesulfonate (n = 2) or 4-pentynyl p-toluenesulfonate (n = 3), K2CO3 in acetone at reflux for 12 h, 96% (n = 1), 68% (n = 2), 61% (n = 3); (d) B10H14 in acetonitrile and toluene at reflux for 7 h, 84% (n = 1), 68% (n = 2), 72% (n = 3); (e) Pd/C and 4.5% HCOOH in MeOH at rt for 3 h, 99%; (f) NaHCO3 in MeOH and H2O at rt for 30 min, quantitative. and 37% overall yields, respectively.
Finally, the third target molecule of ortho-carborane analog of folate (16) was quantitatively prepared from 12a as shown in Scheme 3. The L-glutamic acid moiety was conjugated with the carborane compound (12a) through 2-ethoxy-l-ethoxy-carbonyl-l,2-dihydroxyquinoline (EEDQ)-mediated amide formation reaction. Benzyl group of 14 was selectively deprotected via catalytic transfer hydrogenation in the excellent yield. 15 was also transformed as the sodium salt before in vitro tests.
15 Eventually, the ortho-carborane analog of folate sodium salt (16) was synthesized from the carboranyl benzoic acid (12a) through 3 steps in 96% overall yield (from 4-hydroxybenzoic acid (8) through 8 steps in 66 % overall yield).
All ortho-carboranes as sodium salt (7a, 7b, 13a, 13b, 13c, 16) for BNCT were used for testing in vitro cytotoxicity in three kinds of tumor cells such as B-16 mouse melanoma cell line (i.e., FR positive malignant tumor), U 87 brain tumor cell, and A 431 epidermoid carcinoma cell line (i.e., epidermal growth factor receptor (EGFR) positive malignant tumor), as shown in Figure 2 (also as shown in supplementary materials Table 1 ). Especially, the cytotoxicity of sodium salt (n = 1) (16) was relatively lower than that of the other salts on B-16 and U 87, and that of sodium salt among them, 13a showed relatively low cytotoxicity on A 431. However, toxicities of elongated carboranes (n = 2 and 3) (7b and 13c) were relatively high. It might be the reason that the carborane salts are structurally associated with potent retinoid agonists and antagonist.
16
On the other hands, in comparison with BSH, all carboranes were efficiently accumulated into FR receptor positive tumor cell. Especially, 13a was stably incorporated into the cell after additional incubation as shown in Figure 3 (also as shown in supplementary materials Table 2 ). It was considered to be a good indication of the boron compound as a boron carrier for BNCT.
Conclusion
In summary, all six ortho-carborane analogs of folate were synthesized and characterized for developing a new BNCT agent. Ortho-carborane-conjugated benzoic acid sodium salts (7 and 13) were prepared from 4-aminobenzoic acid in 7 steps in 54% (n = 1) and 36% (n = 3) overall yields, respectively, and from 4-hydroxybenzoic acid in 6 steps in 68% (n = 1), 39% (n = 2), and 37% (n = 3) overall yields, respectively. Furthermore, the ortho-carborane analog of folate sodium salt (16) was efficiently synthesized from the carboranyl acid (12a) in 96% overall yield (66% overall yield from 4-hydroxybenzoic acid, 9). In particular, the carboranes (n = 1) (7a, 13a and 16) have relatively low toxicity and high level of accumulation in FR positive cell. It could be potentially promising BNCT agent to deliver on FR target or internalize in cell nucleus for successful cancer therapy. H NMR spectra were recorded on a VARIAN at 300 MHz. Compounds 2 and 3 were synthesized following a method in reference 1 and 2.
Synthesis of 4-(Formyl-prop-2-ynyl-amino)benzoic Acid Benzyl Ester (4a). To a solution of 4-formylaminobenzoic acid benzyl ester (204 mg, 1.60 mmol) and propargyl bromide (380 mg, 3.20 mmol) in acetone (40 mL) were added potassium carbonate (885 mg, 6.40 mmol) and tetrabutylammonium bromide (515.80 mg, 1.60 mmol). The reaction mixture was heated at reflux for 12 h. After filtration, the solvent was evaporated in vacuo. Then the residue was purified by flash column chromatography using ethyl acetate/n-hexane (1/2) as the eluent to give the title compound 4a (87%) as a white solid. mp 74-79 °C; Synthesis of 4-(Formyl-pent-2-ynyl-amino)benzoic Acid Benzyl Ester (4b). To a solution of 4-formylamino-benzoic acid benzyl ester (204 mg, 1.60 mmol) and 4-pentynyl ptoluenesulfonate (762 mg, 3.20 mmol) in acetone (40 mL) were added potassium carbonate (885 mg, 6.40 mmol) and tetrabutylammonium bromide (515 mg, 1.60 mmol). The reaction mixture was heated at reflux for 12 h. After filtration, the solvent was evaporated in vacuo. Then the residue was purified by flash column chromatography using ethyl acetate/n-hexane (1/2) as the eluent to give the title compound 4b (63%) as a white solid. mp 77-80 °C; The reaction mixture was heated at reflux for 7 h. The solvent was evaporated in vacuo and the residue was purified by flash column chromatography using ethyl acetate/n-hexane (1/2) as the eluent to give the title compound 5a (72%) as a white solid. mp 114-117 °C; Synthesis of 4-[N,N-Formyl-(ortho-carboranylmethyl)-amino]benzoic Acid (6a). A solution of compound 5a (164 mg, 0.4 mmol) and 10% Pd/C (164 mg, 100 wt %) in 4.5% formic acid in methanol (10 mL) was stirred at room temperature (rt) for 3 h. The reaction mixture was filtered by using celite bed and the solvent was evaporated in vacuo to give the title compound 6a (99%) as a white solid. 
Synthesis of 4-[N,N-Formyl-(ortho-carboranylpropyl)-amino]benzoic Acid (6b).
A solution of compound 5b (175 mg, 0.4 mmol) and 10% Pd/C (175 mg, 100 wt %) in 4.5% formic acid in methanol (10 mL) was stirred at rt for 3 h. The reaction mixture was filtered using celite bed and the solvent was evaporated in vacuo to give the title compound 6b (99%) as a white solid. Synthesis of Benzyl 4-hydroxybenzoate (9) . To a solution of 4-hydroxybenzoic acid (6.138 g, 0.045 mmol) in methanol (90 mL) was added cesium carbonate (7.239 g, 0.023 mmol) and the solution was stirred at rt for 10 min. After concentrating the solution, it was azeotroped with toluene to remove remaining water. To the resulting solid was added anhydrous DMF (60 mL) and benzyl bromide (6.3 mL, 0.053 mol), and then the reaction mixture was stirred at rt for 18 h. The reaction progress was monitored by TLC (ethyl acetate and hexane = 1:4). After filtering white solid, the filtrate was concentrated and purified on silica gel flash column chromatography using ethyl acetate/hexane (1/4) to gave the benzyl 4-hydroxybenzoate 9 as a white solids in 93% yield (9.42 g). mp 79.3 °C; Synthesis of 4-(Prop-2-ynyloxy)benzoic Acid Benzyl Ester (10a). To a solution of 4-hydroxybenzoic acid benzyl ester (365 mg, 1.60 mmol) and propargyl bromide (380 mg, 3.20 mmol) in acetone (40 mL) was added potassium carbonate (885 mg, 6.40 mmol). The reaction mixture was heated at reflux for 12 h. After filtration, the solvent was evaporated in vacuo. Then the residue was purified by flash column chromatography using ethyl acetate/n-hexane (1/10) as the eluent to give the title compound 10a (96%) as a white solid. mp 52-56 °C; Synthesis of 4-(But-2-ynyloxy)benzoic Acid Benzyl Ester (10b). To a solution of 4-hydroxy-benzoic acid benzyl ester (365 mg, 1.60 mmol) and 3-butynyl p-toluenesulfonate (717 mg, 3.20 mmol) in acetone (40 mL) was added potassium carbonate (885 mg, 6.40 mmol). The reaction mixture was heated at reflux for 12 h. After filtration, the solvent was evaporated in vacuo. Then the residue was purified by flash column chromatography using ethyl acetate/n-hexane (1/10) Synthesis of 4-(Ortho-carboranylmethyloxy)benzoic Acid Benzyl Ester (11a). To a solution of compound 10a (213 mg, 0.80 mmol) in acetonitrile/toluene (1/3, 16 mL) was added decaborane (116 mg, 1.04 mmol). The reaction mixture was heated at reflux for 7 h, concentrated in vacuo, and purified by flash column chromatography using ethyl acetate/n-hexane (1/10) as the eluent to give the title compound 11a (84%) as a white solid. mp 80-82 °C; Synthesis of 4-(Ortho-carboranylethyloxy)benzoic Acid Benzyl Ester (11b). To a solution of compound 10b (224 mg, 0.80 mmol) in acetonitrile/toluene (1/3, 16 mL) was added decaborane (116 mg, 1.04 mmol). The reaction mixture was heated at reflux for 7 h. The solvent was evaporated in vacuo and the residue was purified by flash column chromatography using ethyl acetate/n-hexane (1/10) as the eluent to give the title compound 11b (68%) as a white solid. mp 96-99 °C; Synthesis of 4-(Ortho-carboranylpropyloxy)benzoic Acid Benzyl Ester (11c). To a solution of compound 10c (235 mg, 0.80 mmol) in acetonitrile/toluene (1/3, 16 mL) was added decaborane (116 mg, 1.04 mmol). The reaction mixture was heated at reflux for 7 h, concentrated in vacuo and chromatographed on silica gel using ethyl acetate/nhexane (1/10) as an eluent to give the title compound 11c (72%) as a white solid. mp 88-91 °C; 
